Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.

OBJECTIVE Tardive dyskinesia is a movement disorder affecting 20%-40% of patients treated chronically with neuroleptic drugs. The dopamine supersensitivity hypothesis cannot account for the time course of tardive dyskinesia or for the persistence of tardive dyskinesia and the associated structural changes after neuroleptics are discontinued. The authors hypothesized that neuroleptics enhance striatal glutamatergic neurotransmission by blocking presynaptic dopamine receptors, which causes neuronal damage as a consequence of oxidative stress. METHOD CSF was obtained from 20 patients with schizophrenia, 11 of whom had tardive dyskinesia. Markers for oxidative stress, including superoxide dismutase, lipid hydroperoxide, and protein carbonyl groups, and markers for excitatory neurotransmission, including N-acetylaspartate, N-acetylaspartylglutamate, aspartate, and glutamate, were measured in the CSF specimens. Patients were also rated for tardive dyskinesia symptoms with the Abnormal Involuntary Movement Scale. RESULTS Tardive dyskinesia patients had significantly higher concentrations of N-acetylaspartate, N-acetylaspartylglutamate, and aspartate in their CSF than patients without tardive dyskinesia when age and neuroleptic dose were controlled for. The significance of the higher levels of protein-oxidized products associated with tardive dyskinesia did not pass Bonferroni correction, however. Tardive dyskinesia symptoms correlated positively with markers of excitatory neurotransmission and protein carbonyl group and negatively with CSF superoxide dismutase activity. CONCLUSIONS These findings suggest that there are elevated levels of oxidative stress and glutamatergic neurotransmission in tardive dyskinesia, both of which may be relevant to the pathophysiology of tardive dyskinesia.

[1]  J. Coyle,et al.  Effects of over- and under-expression of Cu,Zn-superoxide dismutase on the toxicity of glutamate analogs in transgenic mouse striatum , 1998, Brain Research.

[2]  J. Lohr,et al.  A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. , 1996, The Journal of clinical psychiatry.

[3]  J. Coyle,et al.  Oxidative stress in neurodegenerative diseases. , 1996, Annual review of pharmacology and toxicology.

[4]  S. Folstein,et al.  Trial of d-α-tocopherol in Huntington's disease , 1995 .

[5]  J. Coyle,et al.  Tardive dyskinesia and substrates of energy metabolism in CSF. , 1995, The American journal of psychiatry.

[6]  M. Beal,et al.  Aging, energy, and oxidative stress in neurodegenerative diseases , 1995, Annals of neurology.

[7]  J. Coyle,et al.  N-Acetylaspartate in neuropsychiatric disorders , 1995, Progress in Neurobiology.

[8]  A. Cooper,et al.  Glutamate-induced apoptosis results in a loss of striatal neurons in the parkinsonian rat , 1994, Neuroscience.

[9]  S. Mukherjee,et al.  The antioxidant defense system at the onset of psychosis , 1994, Biological Psychiatry.

[10]  A. Volterra,et al.  Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[11]  S. Przedborski,et al.  Neuroleptic medications inhibit complex I of the electron transport chain , 1994, Annals of neurology.

[12]  J. Coyle,et al.  Abnormal acidic amino acids and N-acetylaspartylglutamate in hereditary canine motoneuron disease , 1993, Brain Research.

[13]  J. Coyle,et al.  Oxidative stress, glutamate, and neurodegenerative disorders. , 1993, Science.

[14]  J. Coyle,et al.  Kainic acid-induced lipid peroxidation: protection with butylated hydroxytoluene and U78517F in primary cultures of cerebellar granule cells , 1993, Brain Research.

[15]  W. Glazer,et al.  Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. , 1993, Archives of general psychiatry.

[16]  P. Lavori,et al.  Vitamin E treatment of tardive dyskinesia. , 1993, The American journal of psychiatry.

[17]  J. Kelly,et al.  Neuroleptic medications inhibit complex I of the electron transport chain , 1993, Annals of neurology.

[18]  B. Moghaddam,et al.  Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats , 1993, Neuroscience Letters.

[19]  P. Andrén,et al.  An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. , 1993, Clinical neuropharmacology.

[20]  J. Csernansky,et al.  Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. , 1993, European journal of pharmacology.

[21]  Barry Halliwell,et al.  Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.

[22]  M. Egan,et al.  Treatment of tardive dyskinesia with vitamin E. , 1992, The American journal of psychiatry.

[23]  N. Andreasen,et al.  MRI abnormalities in tardive dyskinesia , 1988, Psychiatry Research: Neuroimaging.

[24]  J. Cadet,et al.  Chronic treatment with prolixin causes oxidative stress in rat brain , 1990, Biological Psychiatry.

[25]  D. Jeste,et al.  Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia , 1990, Biological Psychiatry.

[26]  J. Coyle,et al.  Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis , 1990, Annals of neurology.

[27]  A. Carlsson,et al.  Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease , 1990, Trends in Neurosciences.

[28]  E. Stadtman,et al.  Determination of carbonyl content in oxidatively modified proteins. , 1990, Methods in enzymology.

[29]  J. Olney,et al.  Excitotoxic amino acids and neuropsychiatric disorders. , 1990, Annual review of pharmacology and toxicology.

[30]  J. Cadet,et al.  Possible Involvement of Free Radicals in Neuroleptic‐Induced Movement Disorders Evidence from Treatment of Tardive Dyskinesia with Vitamin E , 1989, Annals of the New York Academy of Sciences.

[31]  C. Meshul,et al.  Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment , 1989, Brain Research.

[32]  E. Levin,et al.  Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia , 1989, Movement disorders : official journal of the Movement Disorder Society.

[33]  J. Lunec,et al.  EVIDENCE OF ENHANCED LIPID PEROXIDATION IN THE CEREBROSPINAL FLUID OF PATIENTS TAKING PHENOTHIAZINES , 1987, The Lancet.

[34]  C. Marsden,et al.  Is the dopamine hypothesis of tardive dyskinesia completely wrong? , 1986, Trends in Neurosciences.

[35]  L. M. Gunne,et al.  Experimental tardive dyskinesia. , 1985, The Journal of clinical psychiatry.

[36]  L. Gunne,et al.  Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis , 1984, Nature.

[37]  R. L. Singhal,et al.  Behavioural and biochemical alterations following haloperidol treatment and withdrawal: The animal model of tardive dyskinesia reexamined , 1983, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[38]  A J Cross,et al.  Abnormal Involuntary Movements in Schizophrenia: Are They Related to the Disease Process or Its Treatment? Are They Associated with Changes in Dopamine Receptors? , 1982, Journal of clinical psychopharmacology.

[39]  J. Kane,et al.  Research diagnoses for tardive dyskinesia. , 1982, Archives of general psychiatry.

[40]  S. Kish,et al.  Effects of chronic administration of antipsychotic drugs on GABA and other amino acids in the mesolimbic area of rat brain. , 1979, Life sciences.

[41]  E. Christensen,et al.  NEUROPATHOLOGICAL INVESTIGATION OF 28 BRAINS FROM PATIENTS WITH DYSKINESIA , 1970, Acta psychiatrica Scandinavica.

[42]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.